PMID- 37305094
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230613
IS  - 2296-861X (Print)
IS  - 2296-861X (Electronic)
IS  - 2296-861X (Linking)
VI  - 10
DP  - 2023
TI  - Therapeutic potential of multifunctional myricetin for treatment of type 2 
      diabetes mellitus.
PG  - 1175660
LID - 10.3389/fnut.2023.1175660 [doi]
LID - 1175660
AB  - Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by chronic 
      hyperglycemia, insulin resistance, and insufficient insulin secretion. It is 
      considered that chronic hyperglycemia causes serious problems due to diabetic 
      complications such as retinopathy, nephropathy, and neuropathy. Primarily, 
      treatment in T2DM is pharmacologically tried by using drugs that are insulin 
      sensitizers, insulin secretagogues, alpha-glucosidase inhibitors, and glucose 
      transporter inhibitors. However, long-term application of these drugs frequently 
      induces various harmful side effects, suggesting that the importance of taking 
      advantage of natural products like phytochemicals. Accordingly, flavonoids, a 
      group of phytochemicals, have attracted attention as components of natural 
      products which are effective in the treatment of several diseases containing T2DM 
      and are strongly recommended as food supplements to ameliorate T2DM-related 
      complications. Several well-studied flavonoids such as quercetin and catechin are 
      known to have anti-diabetic, anti-obesity, and anti-hypertensive actions, 
      although a huge number of flavonoids are still under investigation and their 
      actions are not fully understood. In this situation, myricetin is being shown to 
      be a multiple bioactive compound to prevent and/or suppress hyperglycemia through 
      inhibiting digestion and uptake of saccharides and enhancing insulin secretion as 
      a possible GLP-1 receptor agonist, and to ameliorate T2DM-related complications 
      by protecting endothelial cells from oxidative stress induced by hyperglycemia. 
      In this review, we summarize the multiple effects of myricetin on the targets of 
      T2DM treatment, comparing with different flavonoids.
CI  - Copyright (c) 2023 Niisato and Marunaka.
FAU - Niisato, Naomi
AU  - Niisato N
AD  - Department of Health and Sports Sciences, Faculty of Health and Medical Sciences, 
      Kyoto University of Advanced Science, Kameoka, Japan.
AD  - Medical Research Institute, Kyoto Industrial Health Association, Kyoto, Japan.
FAU - Marunaka, Yoshinori
AU  - Marunaka Y
AD  - Medical Research Institute, Kyoto Industrial Health Association, Kyoto, Japan.
AD  - Research Unit for Epithelial Physiology, Research Organization of Science and 
      Technology, Ritsumeikan University, Kusatsu, Japan.
AD  - Kyoto Prefectural University of Medicine Graduate School of Medical Science, 
      Kyoto, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230526
PL  - Switzerland
TA  - Front Nutr
JT  - Frontiers in nutrition
JID - 101642264
PMC - PMC10251146
OTO - NOTNLM
OT  - GLP-1
OT  - T2DM
OT  - flavonoid
OT  - hyperglycemia
OT  - insulin resistance
OT  - myricetin
OT  - pancreatic beta-cell
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/12 06:42
MHDA- 2023/06/12 06:43
PMCR- 2023/01/01
CRDT- 2023/06/12 04:18
PHST- 2023/02/27 00:00 [received]
PHST- 2023/05/02 00:00 [accepted]
PHST- 2023/06/12 06:43 [medline]
PHST- 2023/06/12 06:42 [pubmed]
PHST- 2023/06/12 04:18 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fnut.2023.1175660 [doi]
PST - epublish
SO  - Front Nutr. 2023 May 26;10:1175660. doi: 10.3389/fnut.2023.1175660. eCollection 
      2023.